0000950170-24-005790.txt : 20240119 0000950170-24-005790.hdr.sgml : 20240119 20240119161505 ACCESSION NUMBER: 0000950170-24-005790 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240117 FILED AS OF DATE: 20240119 DATE AS OF CHANGE: 20240119 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Musso Alan A CENTRAL INDEX KEY: 0001295830 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38978 FILM NUMBER: 24545761 MAIL ADDRESS: STREET 1: FULCRUM THERAPEUTICS, INC. STREET 2: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fulcrum Therapeutics, Inc. CENTRAL INDEX KEY: 0001680581 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474839948 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-651-8851 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 ownership.xml 4 X0508 4 2024-01-17 0001680581 Fulcrum Therapeutics, Inc. FULC 0001295830 Musso Alan A C/O FULCRUM THERAPEUTICS, INC. 26 LANDSDOWNE STREET CAMBRIDGE MA 02139 false true false false Chief Financial Officer false Stock Option (right to buy) 4.01 2024-01-17 4 A false 61822 0.00 A 2024-02-07 2033-08-06 Common Stock 61822 61822 D This performance-based stock option was granted on August 7, 2023 and is subject to the achievement of certain pre-defined performance objectives pertaining to financial and investor relations goals within six months from the grant date, and subject to Mr. Musso continuing to be an "eligible participant" (as defined in Fulcrum Therapeutics, Inc.'s 2022 Inducement Stock Incentive Plan) through the vesting date. All performance objectives were met on January 17, 2024. /s/ Greg Tourangeau as attorney-in-fact for Alan Musso 2024-01-19